A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research

Steven J. Luck, Daniel H. Mathalon, Brian O'Donnell, Matti S. Hmlinen, Kevin M. Spencer, Daniel C. Javitt, Peter J. Uhlhaas

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here, we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: 1) they provide a direct measure of electrical activity during neurotransmission; 2) their high temporal resolutions make it possible to measure neural synchrony and oscillations; 3) they are relatively inexpensive and convenient to record; 4) animal models are readily available for several ERP components; 5) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and 6) feasibility of large N (>500) multisite studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalBiological Psychiatry
Volume70
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Evoked Potentials
Schizophrenia
Biomarkers
Research
Endophenotypes
Synaptic Transmission
Cognition
Psychiatry
Animal Models

Keywords

  • Biomarker
  • ERP
  • event-related potential
  • mismatch negativity
  • P300
  • schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. / Luck, Steven J.; Mathalon, Daniel H.; O'Donnell, Brian; Hmlinen, Matti S.; Spencer, Kevin M.; Javitt, Daniel C.; Uhlhaas, Peter J.

In: Biological Psychiatry, Vol. 70, No. 1, 01.07.2011, p. 28-34.

Research output: Contribution to journalArticle

Luck, Steven J. ; Mathalon, Daniel H. ; O'Donnell, Brian ; Hmlinen, Matti S. ; Spencer, Kevin M. ; Javitt, Daniel C. ; Uhlhaas, Peter J. / A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. In: Biological Psychiatry. 2011 ; Vol. 70, No. 1. pp. 28-34.
@article{4b92d3453af64af89dc2faf0c9e29486,
title = "A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research",
abstract = "New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here, we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: 1) they provide a direct measure of electrical activity during neurotransmission; 2) their high temporal resolutions make it possible to measure neural synchrony and oscillations; 3) they are relatively inexpensive and convenient to record; 4) animal models are readily available for several ERP components; 5) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and 6) feasibility of large N (>500) multisite studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.",
keywords = "Biomarker, ERP, event-related potential, mismatch negativity, P300, schizophrenia",
author = "Luck, {Steven J.} and Mathalon, {Daniel H.} and Brian O'Donnell and Hmlinen, {Matti S.} and Spencer, {Kevin M.} and Javitt, {Daniel C.} and Uhlhaas, {Peter J.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.biopsych.2010.09.021",
language = "English",
volume = "70",
pages = "28--34",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research

AU - Luck, Steven J.

AU - Mathalon, Daniel H.

AU - O'Donnell, Brian

AU - Hmlinen, Matti S.

AU - Spencer, Kevin M.

AU - Javitt, Daniel C.

AU - Uhlhaas, Peter J.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here, we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: 1) they provide a direct measure of electrical activity during neurotransmission; 2) their high temporal resolutions make it possible to measure neural synchrony and oscillations; 3) they are relatively inexpensive and convenient to record; 4) animal models are readily available for several ERP components; 5) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and 6) feasibility of large N (>500) multisite studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.

AB - New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here, we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: 1) they provide a direct measure of electrical activity during neurotransmission; 2) their high temporal resolutions make it possible to measure neural synchrony and oscillations; 3) they are relatively inexpensive and convenient to record; 4) animal models are readily available for several ERP components; 5) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and 6) feasibility of large N (>500) multisite studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.

KW - Biomarker

KW - ERP

KW - event-related potential

KW - mismatch negativity

KW - P300

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79958789050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958789050&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2010.09.021

DO - 10.1016/j.biopsych.2010.09.021

M3 - Article

C2 - 21111401

AN - SCOPUS:79958789050

VL - 70

SP - 28

EP - 34

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 1

ER -